• Markets
    • icon
  • Companies
COV · ASX

CLEO Diagnostics Ltd (ASX:COV)

AU$0.3

 -0.015 (-4.688%)
ASX:Live
26/07/2024 04:10:15 PM
HALO Ords GROWTH AUS All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

COV Overview

COV Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Neutral

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

COV Price Chart

Key Stats

Market Cap

n/a

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

%

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.0 - 0.0

Trade Value (12mth)

N/A

1 week

-4.48%

1 month

6.67%

YTD

72.97%

1 year

0%

All time high

N/A

Key Fundamentals

EPS 3 yr Growth

N/A

EBITDA Margin

N/A

Operating Cashflow

N/A

Free Cash Flow Return

N/A

ROIC

N/A

Interest Coverage

N/A

Quick Ratio

N/A

Other Data

Shares on Issue (Fully Dilluted)

N/A

HALO Sector

Healthcare

Next Company Report Date

N/A

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

N/A

Short Sell (% of issue)

N/A

COV Announcements

Latest Announcements

Date Announcements

24 July 24

Quarterly activities and cashflow report

×

Quarterly activities and cashflow report

26 June 24

Cleo Commences US Regulatory Process with FDA

×

Cleo Commences US Regulatory Process with FDA

24 June 24

Application for quotation of securities - COV

×

Application for quotation of securities - COV

14 June 24

Restricted securities to be released from escrow

×

Restricted securities to be released from escrow

29 May 24

COV Ovarian Cancer Blood Test Outperforms Clinical Benchmark

×

COV Ovarian Cancer Blood Test Outperforms Clinical Benchmark

29 April 24

Quarterly activities and cashflow report

×

Quarterly activities and cashflow report

11 April 24

COV Appoints CRO to Manage US Ovarian Cancer Clinical Trials

×

COV Appoints CRO to Manage US Ovarian Cancer Clinical Trials

02 April 24

CLEO Appoints Partner to Commence U.S. Market Access Program

×

CLEO Appoints Partner to Commence U.S. Market Access Program

25 March 24

Peer-Review Supports CLEOs Ovarian Cancer Detection Tech

×

Peer-Review Supports CLEOs Ovarian Cancer Detection Tech

29 February 24

Appendix 4D and Half Yearly Accounts

×

Appendix 4D and Half Yearly Accounts

20 February 24

Corporate Presentation February 2024

×

Corporate Presentation February 2024

12 February 24

Cleo Completes Design Transfer

×

Cleo Completes Design Transfer

31 January 24

Quarterly activities and cashflow report

×

Quarterly activities and cashflow report

22 November 23

Results of Annual General Meeting

×

Results of Annual General Meeting

06 November 23

Completion of First Triage Test Clinical Validation Study

×

Completion of First Triage Test Clinical Validation Study

06 November 23

Application for quotation of securities - COV

×

Application for quotation of securities - COV

03 November 23

Pause in Trading

×

Pause in Trading

03 November 23

Trading Halt

×

Trading Halt

30 October 23

Quarterly activities and cashflow report

×

Quarterly activities and cashflow report

27 October 23

Restricted securities to be released from escrow

×

Restricted securities to be released from escrow

13 October 23

Application for quotation of securities - COV

×

Application for quotation of securities - COV

09 October 23

Cleo Delivers Early Progress on Development Program

×

Cleo Delivers Early Progress on Development Program

06 October 23

Restricted securities to be released from escrow

×

Restricted securities to be released from escrow

05 October 23

Notice of Annual General Meeting/Proxy Form

×

Notice of Annual General Meeting/Proxy Form

05 October 23

Letter to Shareholders

×

Letter to Shareholders

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

%

DPSg

0.00%

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

COV Shortsell

Frequently Asked Questions

The current share price of CLEO Diagnostics Ltd (COV:ASX) is AU$0.3.
The 52-week high share price for CLEO Diagnostics Ltd (COV:ASX) is AU$0.00.
The 52-week low share price for CLEO Diagnostics Ltd (COV:ASX)? is AU$0.00.
CLEO Diagnostics Ltd (COV:ASX) does not pay a dividend.
CLEO Diagnostics Ltd (COV:ASX) does not pay a dividend.
CLEO Diagnostics Ltd (COV:ASX) does not offer franking credits.
CLEO Diagnostics Ltd (COV:ASX) is classified in the Healthcare.
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.